BioCentury | Mar 30, 2015
Clinical News

Geodon ziprasidone: Phase III started

...a double-blind, placebo-controlled, Japanese Phase III trial to evaluate 40, 60 and 80 mg oral ziprasidone...
...for 6 weeks in about 400 patients. Pfizer markets the product in the U.S. as Geodon...
...Co. Ltd. , Tokyo, Japan Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Geodon ziprasidone ( ME2112...
BioCentury | Feb 2, 2015
Clinical News

Geodon ziprasidone regulatory update

...Geodon ziprasidone ( ME2112 ) Business: Neurology FDA issued a drug safety communication warning that Geodon...
...ziprasidone ( ME2112 ) Business: Neurology FDA issued a drug safety communication warning that Geodon ziprasidone...
BioCentury | Mar 12, 2012
Company News

Dr. Reddy's, Pfizer sales and marketing update

...Dr. Reddy's launched a generic version of Pfizer's Geodon ziprasidone in the U.S. to treat bipolar...
BioCentury | Jul 21, 2011
Financial News

RaQualia off in trading debut

...to two products already marketed in the U.S. -- anti-fungal agent andulafungin and second-generation antipsychotic ziprasidone...
...granted Meiji Seika Kaisha Ltd. (Tokyo, Japan) exclusive rights in Japan to develop and commercialize ziprasidone...
BioCentury | Jul 18, 2011
Finance

RaQualia scores

...rights from Pfizer to three late-stage products. These include the antifungal anidulafungin and second-generation antipsychotic ziprasidone...
...Seika Kaisha Ltd. licensed Japanese rights to ziprasidone, which Pfizer markets in the U.S. as Geodon...
BioCentury | Jul 13, 2011
Top Story

RaQualia raises $79.4M in IPO

...to two products already marketed in the U.S. -- anti-fungal agent andulafungin and second-generation antipsychotic ziprasidone...
...granted Meiji Seika Kaisha Ltd. (Tokyo, Japan) exclusive rights in Japan to develop and commercialize ziprasidone...
BioCentury | Jun 20, 2011
Finance

Reprise for RaQualia

...products that are marketed in the U.S. - the antifungal anidulafungin and the second-generation antipsychotic ziprasidone...
BioCentury | Jun 17, 2011
Financial News

RaQualia resumes IPO plans

...two products already marketed in the U.S. -- anti-fungal agent andulafungin and second generation antipsychotic ziprasidone...
...granted Meiji Seika Kaisha Ltd. (Tokyo, Japan) exclusive rights in Japan to develop and commercialize ziprasidone...
BioCentury | Apr 11, 2011
Clinical News

Abilify aripiprazole neurology data

...Invega from Johnson & Johnson; Saphris from Merck; Fanapt from Vanda and Novartis; and Geodon ziprasidone...
...Tokyo, Japan Pfizer Inc. (NYSE:PFE), New York, N.Y Product: Abilify aripiprazole; Fanapt iloperidone; Geodon ziprasidone...
BioCentury | Mar 28, 2011
Clinical News

Abilify aripiprazole regulatory update

...Otsuka and Bristol-Myers; Fanapt iloperidone from Vanda and Novartis; FazaClo ODT clozapine from Azur; Geodon ziprasidone...
...Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Abilify aripiprazole, Fanapt iloperidone, FazaClo ODT clozapin, Geodon ziprasidone...
Items per page:
1 - 10 of 59